Accenture Ventures, the venture capital arm of Accenture, has invested in 1910 Genetics, a biotechnology company focused on drug discovery using a multimodal artificial intelligence (AI) platform and lab automation.
The financial terms of the investment were not disclosed.
As per the investment agreement, Accenture and 1910 Genetics will offer customised solutions and scalable infrastructure. This partnership aims to help biopharma clients speed up drug target identification, lower costs, and deliver more affordable therapies to patients.
1910 Genetics has developed the proprietary Input-Transform-Output (ITO) platform, a scalable, end-to-end AI solution for drug discovery with applications across all modalities and therapeutic areas.
This multi-AI agent system uses hundreds of models and federated learning, drawing from three proprietary data streams, computational data, wet lab biological data, and wet lab proxy data.
The ITO platform enhances drug discovery by enabling precise target identification, optimising molecule design, and conducting advanced simulations throughout the research and development (R&D) process.
Accenture said this data-driven decision-making approach increases the likelihood of clinical success, shortens experimental iteration cycles, and reduces overall drug development costs.
Accenture Ventures global lead Tom Lounibos said: “Collaborating with 1910 Genetics allows us to integrate our AI expertise with their innovative technology and deliver solutions that can transform drug discovery and improve patient outcomes.”
Accenture’s expertise in scaling AI solutions can help biopharma companies integrate 1910 Genetics’ AI platform into their pipelines.
Both companies will use their experience to drive breakthroughs in therapeutic development. This collaboration seeks to improve drug discovery efficiency and foster innovation within the biopharma industry.
1910 Genetics founder and CEO Jen Nwankwo said: “By collaborating with Accenture, we aim to bring 1910’s AI platform to biopharma companies as an enterprise-wide horizontal infrastructure that breaks down barriers in data, model, and computing power to accelerate the discovery and development of both small and large molecule therapeutics across all therapeutic areas.”
As part of this announcement, Petra Jantzer and Tom Lounibos will join 1910 Genetics’ business advisory board.
Additionally, 1910 Genetics will participate in Accenture Ventures’ Project Spotlight, a programme for startups that develop new enterprise technologies.
In August, Accenture Ventures announced an investment in California-based Earli to advance technologies for early cancer detection.
